| http://www.w3.org/ns/prov#value | - Its approval was a landmark event in the history of melanoma treatment, as it was the first therapy ever to demonstrate improved overall survival in a randomized phase III trial for patients with metastatic melanoma.1 Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4).
|
